What does Delcath Systems, Inc. do?
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while…
What is Delcath Systems, Inc.'s P/E and P/B ratio?
Delcath Systems, Inc. has a P/E ratio of 1475.0 and a P/B ratio of 4.22.
What is Delcath Systems, Inc.'s debt-to-equity ratio?
Delcath Systems, Inc. has a debt-to-equity ratio of 0.02.
How much does Delcath Systems, Inc. owe compared with what it owns?
Delcath Systems, Inc. owes $0.12 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Delcath Systems, Inc.'s Positivity rank?
Delcath Systems, Inc. is ranked #5,050 of 6,774 companies globally and #2,676 of 4,000 in United States on PositoAI, with a Positivity Score of 18,482.
Does Delcath Systems, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Delcath Systems, Inc..
Where can I read the latest news about Delcath Systems, Inc.?
Recent headlines about Delcath Systems, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Delcath Systems, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Delcath Systems, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.